Neuroscience companies criticize FDA for drug-approval delays

11/10/2008 | Wall Street Journal, The

Firms affiliated with the Neurotechnology Industry Organization expressed concern over the FDA's failure to meet some drug-approval deadlines and to schedule discussions with companies. Such delays and the agency's tight focus on product safety can slow down drug development for as long as six months, said Ron Cohen, CEO of Acorda Therapeutics. The firm plans in early 2009 to seek FDA approval for Fampridine-SR, a treatment for multiple sclerosis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN